Matches in Wikidata for { <http://www.wikidata.org/entity/Q66404601> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q66404601 description "clinical trial" @default.
- Q66404601 description "ensayu clínicu" @default.
- Q66404601 description "klinisch onderzoek" @default.
- Q66404601 description "клінічне випробування" @default.
- Q66404601 name "Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease" @default.
- Q66404601 name "Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease" @default.
- Q66404601 type Item @default.
- Q66404601 label "Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease" @default.
- Q66404601 label "Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease" @default.
- Q66404601 prefLabel "Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease" @default.
- Q66404601 prefLabel "Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease" @default.
- Q66404601 P1050 Q66404601-493DF91F-FBC1-44B8-BB7D-7EACDC0A618D @default.
- Q66404601 P1132 Q66404601-5FC96E53-2472-4F6C-8E58-0D1F19269AD4 @default.
- Q66404601 P1476 Q66404601-110DA852-22C7-4933-912A-1A449DA4AECA @default.
- Q66404601 P17 Q66404601-2F9110EF-95B7-40DD-9433-1825C9AE9912 @default.
- Q66404601 P17 Q66404601-3F876D43-1152-41F3-8795-8A71C8C2EF81 @default.
- Q66404601 P17 Q66404601-7163BE11-78CD-4900-88CD-9C2A37B5A030 @default.
- Q66404601 P17 Q66404601-76CB3D78-BCFC-4F3C-A942-B8039BDBC4B5 @default.
- Q66404601 P17 Q66404601-92FA5A0B-A0C3-44C5-9E0A-44C3981E76E9 @default.
- Q66404601 P17 Q66404601-940C995F-4139-4AEB-B527-296FB7000701 @default.
- Q66404601 P17 Q66404601-96143014-DCC4-44E5-8676-F2797666EF14 @default.
- Q66404601 P17 Q66404601-A42368D8-818C-4F05-BB0F-E145BD51CB5E @default.
- Q66404601 P17 Q66404601-AC4E27BC-ACD4-4E4E-BCFD-C312CEEB5A6E @default.
- Q66404601 P17 Q66404601-C9FD4B2A-6FBD-458C-99E8-E52C7F941D94 @default.
- Q66404601 P17 Q66404601-CD5BE121-10FF-48CC-8DF8-F1A92AF41BEE @default.
- Q66404601 P17 Q66404601-DEC047B9-EFDB-41F8-8A48-9882FE081051 @default.
- Q66404601 P17 Q66404601-E7FEB0E5-F8E6-4AE0-8965-5FE3DCC742E7 @default.
- Q66404601 P17 Q66404601-E99C45CB-D3FF-42FE-86A1-14E140091EF7 @default.
- Q66404601 P17 Q66404601-F7D5AC1D-B773-4E8E-BCBD-594BDAB4FE63 @default.
- Q66404601 P1813 Q66404601-06DB34E5-B4D7-4751-9909-732DA79889F5 @default.
- Q66404601 P2899 Q66404601-41C2333E-1FBB-421A-9F34-FAC08D6DCE5F @default.
- Q66404601 P3098 Q66404601-62C9AD0F-D5D7-4275-968D-B17C5BC81C9D @default.
- Q66404601 P31 Q66404601-069C1150-773E-4A4F-8C79-965AC04F87C6 @default.
- Q66404601 P580 Q66404601-FF1B1044-F9DC-440B-BAE2-231D70675403 @default.
- Q66404601 P582 Q66404601-0CC21A3B-70FA-4C9E-89AF-2F3CED631AD6 @default.
- Q66404601 P6099 Q66404601-55D21E21-9F6D-44E2-95FD-E924EC8D8440 @default.
- Q66404601 P8363 Q66404601-6462D887-0910-4613-ACDE-271570A41802 @default.
- Q66404601 P1050 Q170990 @default.
- Q66404601 P1132 "+1575" @default.
- Q66404601 P1476 "A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy" @default.
- Q66404601 P17 Q145 @default.
- Q66404601 P17 Q155 @default.
- Q66404601 P17 Q183 @default.
- Q66404601 P17 Q191 @default.
- Q66404601 P17 Q211 @default.
- Q66404601 P17 Q218 @default.
- Q66404601 P17 Q219 @default.
- Q66404601 P17 Q28 @default.
- Q66404601 P17 Q30 @default.
- Q66404601 P17 Q36 @default.
- Q66404601 P17 Q37 @default.
- Q66404601 P17 Q414 @default.
- Q66404601 P17 Q739 @default.
- Q66404601 P17 Q865 @default.
- Q66404601 P17 Q96 @default.
- Q66404601 P1813 "CREDO 2" @default.
- Q66404601 P2899 "+18" @default.
- Q66404601 P3098 "NCT02760407" @default.
- Q66404601 P31 Q30612 @default.
- Q66404601 P580 "2016-05-01T00:00:00Z" @default.
- Q66404601 P582 "2019-12-01T00:00:00Z" @default.
- Q66404601 P6099 Q42824827 @default.
- Q66404601 P8363 Q78089383 @default.